Overview / Abstract: |
Dr. Paul Feuerstadt introduces the concept of non-antimicrobial therapies for treatment of C. difficile infection and prevention of recurrence. Discussion focuses on the efficacy of available monoclonal antibodies and available and emerging microbiota replacement therapies |
Expiration |
Jul 22, 2021 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Physician CME, Physician Assistant CME |
Format |
Webinar / Webcast / Video |
Credits / Hours |
.50 |
Accreditation |
ACCME |
Presenters / Authors / Faculty |
Paul Feuerstadt, MD, FACG, AGAF |
Activity Specialities / Related Topics |
Gastroenterology / GI, Infectious Disease, Primary Care |
Sponsors / Supporters / Grant Providers |
Sponsored by the Academy for Continued Healthcare Learning (ACHL). Supported by educational grants from Ferring Pharmaceuticals Inc., and Merck & Company. |
Keywords / Search Terms |
ACHL C. difficile, CME/CE/CPE, ID-week, Dr. Feuerstadt, Dr. Khanna, Dr. Garey, microbiome, gut microbiota, role of the gut, recurrent, infections, infectious disease, physician, pharmacists, , microbiota restoration therapy, FMT, fecal microbiota transplant, intestinal microbiota transplant, fecal microbiota for transplantation, bacterial infections, gram-negative, clinical cases, fidaxomicin, vancomycin Free CE CME |